ZHONGSHENGYAOYE(SZ:002317)2025-12-08 09:48Group 1: Investor Relations Activity - The investor relations activity involved a meeting with analysts from Morgan Fund Management, Guolian Minsheng Securities, and Shenzhen Yide Global Fund Management on December 8, 2025 [1] - The meeting was held in the company conference room and included discussions on the company's new drug inclusion in the national medical insurance directory [1] Group 2: New Drug Inclusion - The innovative drug, Olanavir Tablets (brand name: Anruiwei®), was included in the National Medical Insurance Directory on December 7, 2025, following negotiations with the National Healthcare Security Administration [1][3] - Other core products such as Liraglutide Tablets and various capsules were also included in this directory, enhancing their market accessibility [1] Group 3: Drug Characteristics - Olanavir Tablets are the world's first oral drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for adult patients with uncomplicated influenza [3][4] - The drug demonstrates rapid symptom relief, strong antiviral effects, and low resistance rates, with positive results from clinical trials [4][5] Group 4: Sales and Marketing Strategy - The company plans to enhance marketing through three dimensions: building an academic ecosystem, upgrading data services, and implementing key project practices [8] - The inclusion of Olanavir Tablets in the National Medical Insurance Directory is expected to positively impact market promotion and long-term business development [8] Group 5: Pediatric Development Plans - The company is developing Olanavir Granules for children and adolescents, with ongoing Phase III clinical trials for both adolescents (ages 12-17) and children (ages 2-11) [9][11] - The trials aim to establish a comprehensive treatment matrix for influenza across all age groups [11] Group 6: Other Drug Developments - RAY1225 injection, an innovative dual-agonist drug for type 2 diabetes and obesity, has shown positive results in Phase II clinical trials and is progressing to Phase III trials [12][13] - ZSP1601 tablets, targeting metabolic dysfunction-related fatty liver disease, have completed early clinical trials with promising results and are moving into Phase IIb trials [15][16] Group 7: Research and Development Pipeline - The company is focusing on innovative drug development in respiratory and metabolic diseases, with projects targeting unmet clinical needs [16][18] - Ongoing research includes a new drug for respiratory syncytial virus (RSV) and various GLP-1 receptor agonists, with clinical candidates identified and preclinical studies underway [16][18]